Screener
Tango Therapeutics TNGX EBITDA
Discontinued — last reported Q1 '26
EBITDA at other companies
Other financials
Where this comes from
Calculated from Tango Therapeutics’s reported figures.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
FAQ
- What is Tango Therapeutics's EBITDA?
- Tango Therapeutics (TNGX) reported EBITDA of -$48.31M in Q1 2026.
- How has Tango Therapeutics's EBITDA changed year-over-year?
- Tango Therapeutics's EBITDA decreased by 15.3% year-over-year, from -$41.91M to -$48.31M.
- What is the long-term trend for Tango Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Tango Therapeutics's EBITDA has grown at a 27.1% compound annual growth rate (CAGR), from -$41.72M to -$109.01M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Tango Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude